TAK

TAK

USD

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$13.660+0.060 (0.441%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
日本

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$13.600

最高

$13.680

最低

$13.560

交易量

2.79M

公司基本面

市值

43.2B

行業

Drug Manufacturers - Specialty & Generic

國家

Japan

交易統計

平均交易量

2.88M

交易所

NYQ

貨幣

USD

52週範圍

最低 $12.8當前 $13.660最高 $15.69

相關新聞

BusinessWire

New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Findings Reinforce QDENGA's Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease Exposure Takeda is

查看更多
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
BusinessWire

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic Erosion of VYVANSE® and FX Headwind Core Operating Profit Declined 8.8% at CER in the

查看更多
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
BusinessWire

HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation

Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the HYQVIA

查看更多
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
PR Newswire

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation IO and ADC...

查看更多
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
BusinessWire

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program Takeda to Lead

查看更多
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors